Boron in drug design: Recent advances in the development of new therapeutic agents

Autor(es)

Santos Fernandes, Guilherme Felipe ^{[1, 2, 3]} ; Denny, William Alexander ^[2] ; Dos Santos, Jean Leandro ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Sch Pharmaceut Sci, BR-14800903 Araraquara - Brazil

^[2] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland - New Zealand

^[3] Sao Paulo State Univ, Inst Chem, BR-14800060 Araraquara - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 179, p. 791-804, OCT 1 2019.
• Citações Web of Science: 1

Resumo

Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade (R)), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin (R)) for the treatment of onychomicosis and crisaborole (Eucrisa (R)) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years. (C) 2019 Elsevier Masson SAS. All rights reserved. (AU)

• Processo FAPESP: 18/11079-0 - Síntese e atividade antituberculose de novos derivados N-óxidos planejados para o tratamento da tuberculose multirresistente
• Beneficiário: Jean Leandro dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/09502-7 - Planejamento, síntese e atividade antituberculose de novas oxazolidinonas úteis ao tratamento da tuberculose multirresistente
• Beneficiário: Guilherme Felipe dos Santos Fernandes
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 18/17739-2 - Síntese de Novos Derivados de Nitroimidazooxazina Planejados como Agentes Antituberculose
• Beneficiário: Guilherme Felipe dos Santos Fernandes
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado